This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

China NT Pharma Group Valuation

Q: What is the Fair Price of 2965 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

2965 (HK$0.3) is trading below our estimate of [[fair value]] (HK$4.62)

Is 2965 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 2965 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 2965 (HK$0.3) is trading below our estimate of fair value (HK$4.62)

Significantly Below Fair Value: 2965 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2965?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 2965. This is calculated by dividing 2965's market cap by their current preferred multiple.
What is 2965's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	n/a

2965 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	55.8x
Enterprise Value/EBITDA	-8x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 2965's PS Ratio compare to its peers?

The above table shows the PS ratio for 2965 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	75.7x
858 Extrawell Pharmaceutical Holdings	2.1x	n/a	HK$124.3m
1889 Sanai Health Industry Group	0.9x	n/a	HK$91.7m
1312 Kontafarma China Holdings	0.2x	n/a	HK$184.4m
575 Regent Pacific Group	299.6x	n/a	HK$118.8m
2965 China NT Pharma Group	9.2x	n/a	HK$68.7m

Price-To-Sales vs Peers: 2965 is good value based on its Price-To-Sales Ratio (9.2x) compared to the peer average (10.1x).

Price to Earnings Ratio vs Industry

How does 2965's PE Ratio compare vs other companies in the HK Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	10.9%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	10.9%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: 2965 is expensive based on its Price-To-Sales Ratio (9.2x) compared to the Hong Kong Pharmaceuticals industry average (1.2x).

Price to Sales Ratio vs Fair Ratio

What is 2965's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2965 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	9.2x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 2965's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.